Nurix Therapeutics, Inc. (NRIX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Nov 30
In fiscal 2025, Nurix Therapeutics, Inc. reported revenue of $83.98M, up 54.0% from the prior year. The company ran a net loss, with a net margin of -314.9%. It held $688.13M in total assets against $149.39M in total liabilities.
Key ratios (FY2025)
-340.2%
Operating margin
-314.9%
Net margin
-49.1%
Return on equity
+54.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | — | — | — | — |
| Operating Income | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M | -$64.98M | -$22.24M | — |
| Net Income | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M | -$43.24M | -$21.70M | — |
| EPS (Diluted) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | — | — | — |
| Total Assets | $688.13M | $669.34M | $355.60M | $416.76M | $476.77M | $396.34M | $44.05M | — |
| Total Liabilities | $149.39M | $142.35M | $155.10M | $113.06M | $134.47M | $106.07M | $53.57M | — |
| Shareholders' Equity | $538.75M | $526.99M | $200.49M | $303.70M | $342.30M | $290.27M | -$57.71M | -$36.85M |
| Cash & Equivalents | $246.96M | $110.00M | $54.63M | $64.47M | $80.51M | $119.36M | $34.82M | — |
| Operating Cash Flow | -$249.47M | -$172.58M | -$81.36M | -$159.81M | -$84.36M | -$80.0K | $601.0K | — |
| Capital Expenditures | $14.00M | $9.27M | $8.40M | $12.24M | $5.66M | $4.55M | $1.65M | — |
| Shares Outstanding | 101.81M | 75.87M | 48.72M | 47.17M | 44.66M | 38.86M | 3.60M | — |
| Dividends Per Share | $0.00 | $0.00 | — | — | — | $0.00 | $0.00 | — |